Company Overview

Immunic, Inc. (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company focused on the development of orally administered, small-molecule therapies for chronic inflammatory and autoimmune diseases. The company operates within the biotechnology and pharmaceutical research industry, with a strategic emphasis on immune-mediated conditions that have significant unmet medical needs.

The company’s core value is driven by its development pipeline, particularly its lead asset vidofludimus calcium (IMU-838), an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor. Immunic targets diseases such as multiple sclerosis, inflammatory bowel disease, and other autoimmune disorders. The company was founded in 2016 through the merger of privately held Immunic Therapeutics and publicly listed Vital Therapies, evolving into a focused immunology platform company headquartered in the United States.

Business Operations

Immunic’s operations are centered on drug discovery, clinical development, and regulatory advancement of its proprietary pipeline. The company operates primarily as a research and development organization and does not generate product revenue, relying instead on capital markets to fund operations. Its primary operating segments are clinical development and preclinical research, with resources allocated across multiple autoimmune indications.

The company’s key assets include vidofludimus calcium (IMU-838), IMU-856, and IMU-381, which target immune and gastrointestinal pathways. Immunic conducts clinical trials both domestically and internationally, working with contract research organizations and academic partners. The company maintains subsidiaries in Germany to support European clinical and regulatory activities, reflecting its transatlantic operational model.

Strategic Position & Investments

Immunic’s strategic direction is focused on advancing vidofludimus calcium (IMU-838) through late-stage clinical development, particularly for relapsing multiple sclerosis and progressive multiple sclerosis. The company positions its lead candidate as a differentiated oral therapy with a favorable safety profile compared to existing immunomodulatory treatments, which is central to its competitive strategy.

The company has made targeted investments in expanding its pipeline through internal research rather than large-scale acquisitions. Its portfolio reflects a concentration on small-molecule immunology rather than biologics, which Immunic views as advantageous in terms of oral delivery, manufacturing scalability, and patient adherence. Emerging areas of focus include intestinal barrier function and immune-metabolic modulation.

Geographic Footprint

Immunic is headquartered in New York, United States, with significant operational and scientific activities in Germany, where much of its research heritage originated. This dual presence supports both U.S. capital markets access and European clinical development capabilities.

The company’s clinical trials are conducted across North America and Europe, giving Immunic a multinational footprint despite its relatively small corporate size. Its international operations are primarily research- and trial-focused rather than commercial, as the company has not yet launched an approved product.

Leadership & Governance

Immunic is led by an executive team with experience in immunology, drug development, and public company management. The leadership emphasizes scientific rigor, capital discipline, and a focused pipeline strategy aimed at addressing high-value autoimmune indications.

Key executives include:

• Daniel Vitt, PhD – Chief Executive Officer
• Dr. Andreas Mühlbacher – President and Chief Scientific Officer
• Meena Ramachandran, MD – Chief Medical Officer
• David J. Wilson – Chief Financial Officer

The board and management team collectively guide the company’s long-term vision of developing differentiated oral immunotherapies while advancing assets through value-inflecting clinical milestones.